Naringenin inhibits the growth of Dictyostelium and MDCK‐derived cysts in a TRPP2 (polycystin‐2)‐dependent manner. (May 2014)
- Record Type:
- Journal Article
- Title:
- Naringenin inhibits the growth of Dictyostelium and MDCK‐derived cysts in a TRPP2 (polycystin‐2)‐dependent manner. (May 2014)
- Main Title:
- Naringenin inhibits the growth of Dictyostelium and MDCK‐derived cysts in a TRPP2 (polycystin‐2)‐dependent manner
- Authors:
- Waheed, A
Ludtmann, M H R
Pakes, N
Robery, S
Kuspa, A
Dinh, C
Baines, D
Williams, R S B
Carew, M A - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12443-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>Identifying and characterizing potential new therapeutic agents to target cell proliferation may provide improved treatments for neoplastic disorders such as cancer and polycystic diseases.</p> </sec> <sec id="bph12443-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>We used the simple, tractable biomedical model <italic>Dictyostelium</italic> to investigate the molecular mechanism of naringenin, a dietary flavonoid with antiproliferative and chemopreventive actions <italic>in vitro</italic> and in animal models of carcinogenesis. We then translated these results to a mammalian kidney model, Madin‐Darby canine kidney (MDCK) tubule cells, grown in culture and as cysts in a collagen matrix.</p> </sec> <sec id="bph12443-sec-0003" sec-type="section"> <title>Key Results</title> <p>Naringenin inhibited <italic>Dictyostelium</italic> growth, but not development. Screening of a library of random gene knockout mutants identified a mutant lacking TRPP2 (polycystin‐2) that was resistant to the effect of naringenin on growth and random cell movement. TRPP2 is a divalent transient receptor potential cation channel, where mutations in the protein give rise to type 2 autosomal dominant polycystic kidney disease (ADPKD). Naringenin inhibited MDCK cell growth and inhibited cyst growth. Knockdown of<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12443-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>Identifying and characterizing potential new therapeutic agents to target cell proliferation may provide improved treatments for neoplastic disorders such as cancer and polycystic diseases.</p> </sec> <sec id="bph12443-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>We used the simple, tractable biomedical model <italic>Dictyostelium</italic> to investigate the molecular mechanism of naringenin, a dietary flavonoid with antiproliferative and chemopreventive actions <italic>in vitro</italic> and in animal models of carcinogenesis. We then translated these results to a mammalian kidney model, Madin‐Darby canine kidney (MDCK) tubule cells, grown in culture and as cysts in a collagen matrix.</p> </sec> <sec id="bph12443-sec-0003" sec-type="section"> <title>Key Results</title> <p>Naringenin inhibited <italic>Dictyostelium</italic> growth, but not development. Screening of a library of random gene knockout mutants identified a mutant lacking TRPP2 (polycystin‐2) that was resistant to the effect of naringenin on growth and random cell movement. TRPP2 is a divalent transient receptor potential cation channel, where mutations in the protein give rise to type 2 autosomal dominant polycystic kidney disease (ADPKD). Naringenin inhibited MDCK cell growth and inhibited cyst growth. Knockdown of TRPP2 levels by siRNA in this model conferred partial resistance to naringenin such that cysts treated with 3 and 10 μM naringenin were larger following TRPP2 knockdown compared with controls. Naringenin did not affect chloride secretion.</p> </sec> <sec id="bph12443-sec-0004" sec-type="section"> <title>Conclusions and Implications</title> <p>The action of naringenin on cell growth in the phylogenetically diverse systems of <italic>Dictyostelium</italic> and mammalian kidney cells, suggests a conserved effect mediated by TRPP2 (polycystin‐2). Further studies will investigate naringenin as a potential new therapeutic agent in ADPKD.</p> </sec> <sec id="bph12443-sec-5001" sec-type="relatedArticles"> <title>Linked Articles</title> <p>This article is part of a themed section on the pharmacology of TRP channels. To view the other articles in this section visit <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bph.2014.171.issue-10" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">http://dx.doi.org/10.1111/bph.2014.171.issue‐10</ext-link></p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of pharmacology. Volume 171:Number 10(2014:May)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 171:Number 10(2014:May)
- Issue Display:
- Volume 171, Issue 10 (2014)
- Year:
- 2014
- Volume:
- 171
- Issue:
- 10
- Issue Sort Value:
- 2014-0171-0010-0000
- Page Start:
- 2659
- Page End:
- 2670
- Publication Date:
- 2014-05
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.12443 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3717.xml